Pylum Biosciences, a San Francisco-based medical firm, develops unique, adaptable bactericidal proteins targeting specific pathogens, with minimal off-target effects.
Dave Martin is one of the people in biotech who has truly seen it all. In the ’80s, the industry’s early days, he was head of R&D at Genentech. His latest passion, which he’s pursuing with business partner Jim Knighton, is taking shape at a lean startup in South San Francisco called AvidBiotics.
The page cites a Centers for Disease Control and Prevention estimate of around 500 million acute bacterial infections worldwide each year that require some form of antibacterial therapy.
The page reports on an animal study of Avidocin proteins for preventing and treating E. coli O157 diarrhea. The study examined a targeted antibacterial protein against E. coli O157:H7 and food-borne bacterial infections.
AvidBiotics and researchers at Harvard Medical School’s Brigham and Women’s Hospital said its Avidocin proteins could prevent and treat E. coli-related diarrhea and intestinal inflammation.
AvidBiotics received two National Institutes of Health grants totaling $1 million to further develop its Avidocin platform. The grants add to three previous grants for the company’s anti-infectious disease technologies.
The board consists of co-founders Martin, Knighton, and Jeffery F. Miller, and Dr. Barbosa, elected in 2018. Kevin Cameron brings an entrepreneurial, legal, and transactional background.
Pylum Biosciences developed and patented the Avidocin platform, which generates bactericidal protein complexes targeting specific bacterial pathogens. The platform can be modified to target emerging strains as their genome sequences become available.
AvidBiotics has two product platforms. Its Avidocin proteins are targeted bactericidal agents for treating or preventing bacterial infections and manipulating bacterial populations.
Pylum Biosicences has developed and patented an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens.